Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about its results for the year ended 31st Dec 2016 and also the award of a grant under the EU’s Horizon 2020 programme. Ewan talks us through the highlights, provides more detail around the grant, talks us through some new products that will be launched very soon and explains what reaching the 30 account platform target has meat for the company and company resources are to be redeployed to best serve its American customer base.
Deltex Medical Group Plc manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.